← Back to Search

Viscosupplementation

Hyaluronic Acid (HA) Injection for Osteoarthritis

N/A
Waitlist Available
Led By Brad J Monteleone, Physician
Research Sponsored by LifeMark Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical
19-75 years of age (inclusive)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (pre-injection), 1, 3 and 6 weeks, and 3 and 6 months post injection
Awards & highlights

Study Summary

Do differences exist between patients who receive a single intra-articular injection of corticosteroid versus patients who receive a single intra-articular injection of hyaluronic acid for the treatment of knee osteoarthritis at 1, 3 and 6 weeks, and 3 and 6 months post injection?

Eligible Conditions
  • Osteoarthritis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (pre-injection), 1, 3 and 6 weeks, and 3 and 6 months post injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-injection), 1, 3 and 6 weeks, and 3 and 6 months post injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The will be "pain while walking for approximately 30 minutes on a flat surface today" as reported by the patient on a 100mm unmarked VAS (0 = no pain; 100 = worst pain possible).
Secondary outcome measures
Pain at rest or with stairs as reported byu the patient on a VAS

Trial Design

2Treatment groups
Active Control
Group I: Hyaluronic Acid (HA) InjectionActive Control1 Intervention
Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's). All injections will be administered as outlined on the company label. Aspiration of the knee will not be performed.
Group II: Corticosteroid InjectionActive Control1 Intervention
Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.

Find a Location

Who is running the clinical trial?

LifeMark HealthLead Sponsor
1 Previous Clinical Trials
88 Total Patients Enrolled
Brad J Monteleone, PhysicianPrincipal InvestigatorUBC - Department of Family Practice

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study Comparing Viscosupplementation and Corticosteroid Injections for Knee Osteoarthritis
2010. "A Study Comparing Viscosupplementation and Corticosteroid Injections for Knee Osteoarthritis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01132677.
All > Osteoarthritis > Knee Osteoarthritis
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top